Furthermore, the simulations demonstrated that the proposed dosing regimens of 100 mg OD are appropriate for NSCLC patients with wild-type ALK and three ALK mutations, even in the presence of brain metastasis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.